Nuveen Asset Management, LLC Theseus Pharmaceuticals, Inc. Transaction History

Nuveen Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.66 - $10.04 $1,542 - $5,823	-580 Reduced 0.7%	81,898 $220,000
Q2 2023 Aug 14, 2023	BUY	$7.28 - $11.82 $441,379 - $716,634	60,629 Added 277.49%	82,478 $769,000
Q4 2022 Feb 14, 2023	SELL	$4.69 - $8.36 $69,351 - $123,619	-14,787 Reduced 40.36%	21,849 $109,000
Q3 2022 Nov 14, 2022	BUY	$5.7 - $8.68 $28,032 - $42,688	4,918 Added 15.51%	36,636 $212,000
Q2 2022 Aug 15, 2022	BUY	$5.04 - $14.05 $71,688 - $199,847	14,224 Added 81.31%	31,718 $175,000
Q4 2021 Feb 14, 2022	BUY	$8.98 - $20.09 $157,096 - $351,454	17,494 New	17,494 $222,000

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.